Insight Molecular Diagnostics Inc.

Name: Insight Molecular Diagnostics Inc. standardized financial statements, quarterly
Creator: Listed

IMDXNasdaqCIK 1642380HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$239.0k, Q2 FY2026

Operating income−$11.4m, Q2 FY2026

Net income−$11.3m, Q2 FY2026

Insight Molecular Diagnostics Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.4	0.3	0.2	0.1	0.1	1.5	2.1	0.5	0.3	1.1	0.0	0.2
Cost of revenue	$m	0.2	0.4	0.1	0.0	0.0	0.9	0.8	0.2	0.1	0.6	0.0	0.1
Gross profit	$m	0.2	(0.1)	0.0	0.1	0.1	0.6	1.3	0.3	0.1	0.5	0.0	0.2
Research and development	$m	2.2	2.5	2.3	2.5	2.8	2.3	2.9	3.3	3.9	5.8	5.0	4.5
Operating income	$m	(6.5)	(16.2)	(9.3)	(4.6)	(13.5)	(33.6)	(6.8)	(9.8)	(11.0)	(23.4)	(4.4)	(11.4)
Income tax	$m	not reported	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(6.5)	(16.0)	(9.1)	(4.5)	(13.5)	(33.5)	(6.7)	(9.7)	(10.9)	(23.0)	(4.3)	(11.3)
Diluted EPS	$ per share	(0.81)	not reported	(1.13)	(0.36)	(0.98)	not reported	(0.26)	(0.30)	(0.34)	not reported	(0.12)	(0.31)
Basic EPS	$ per share	(0.81)	not reported	(1.13)	(0.36)	(0.98)	not reported	(0.26)	(0.30)	(0.34)	not reported	(0.12)	(0.31)

Balance sheet

Cash and equivalents$17.8m, Q2 FY2026

Shareholders' equity−$21.3m, Q2 FY2026

Insight Molecular Diagnostics Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	13.8	9.4	5.6	9.3	3.4	8.6	31.0	24.3	18.7	11.6	28.2	17.8
Current assets	$m	16.9	10.7	6.5	10.0	4.8	11.8	36.3	26.8	21.4	15.3	30.5	20.5
Total assets	$m	81.6	74.9	71.0	74.7	70.2	35.1	60.4	50.5	43.9	25.8	40.4	29.4
Current liabilities	$m	8.0	7.2	8.3	7.2	9.1	7.3	9.7	6.7	7.7	12.1	12.0	10.3
Total liabilities	$m	39.1	49.3	54.1	52.0	60.5	47.4	50.1	49.4	53.1	57.2	51.1	50.7
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	36.1	20.5	11.6	22.7	9.7	(12.3)	10.2	1.1	(9.2)	(31.5)	(10.7)	(21.3)

Cash flow

Operating cash flow−$9.3m, Q2 FY2026

Capital expenditure$779.0k, Q2 FY2026

Insight Molecular Diagnostics Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,769)	(4,424)	(3,830)	(5,978)	(5,530)	(5,351)	(5,839)	(6,174)	(4,626)	(5,545)	(7,639)	(9,268)
Capital expenditure	$k	not reported	264	24.0	191	87.0	214	307	349	1,050	1,479	613	779

Diluted shares (weighted)36.75m, Q2 FY2026

Insight Molecular Diagnostics Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	0.0	6.0	8.1	8.3	8.3	12.9	13.7	25.7	32.0	32.0	34.5	36.8

Shares outstanding: 32.72m at Aug 3, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.